Finding the Achilles' heel of cancer cells

March 17, 2020

The key to effective cures for cancers is to find weak points of cancer cells that are not found in non-cancer cells. Researchers at the Tokyo Metropolitan Institute of Medical Science found that cancerous and non-cancerous cells depend on different factors for survival when their DNA replication is blocked. Drugs that inhibited the survival factor required by cancer cells would selectively make cancer cells more vulnerable to replication inhibition.

Copying the 3 billion base-pairs of the human genome (DNA replication) takes 6-8 hrs. During this time, cells can encounter many problems that interfere with the copying process. DNA consists of long chains of nucleotide bases, and obstacles such as DNA interacting compounds, damaged bases, cross-linked DNA strands, reductions in nucleotide precursors, blockage by DNA binding proteins, unusual secondary structures of template DNAs, and collision with transcription, can all contribute to blocking replication. It is essential for growing cells to overcome these problems to ensure that the entire genome is copied accurately. If cells cannot cope with these crises, the genome is likely to undergo changes that could cause cancer cells to develop.

Cells have evolved elaborate mechanisms to protect against damage from faulty DNA replication. When DNA replication machinery encounters an obstacle preventing replication, it activates a safety mechanism known as replication checkpoint. Replication checkpoint stops DNA replication and activates repair pathways. A critical protein in this process is called Claspin. When replication is blocked, a phosphate is covalently attached to Claspin, in a process known as phosphorylation. Phosphorylation of Claspin is a critical first step in activating replication checkpoint.

Recently, Chi-Chun Yang and his colleagues at the Tokyo Metropolitan Institute of Medical Science determined how Claspin is phosphorylated. Their findings were reported in the 2019 December issue of E-life. By using genetically modified animals and cells as well as biochemical analyses with purified proteins, they found that when DNA replication is blocked in cancer cells, a protein called Cdc7 predominantly phosphorylates Claspin to activate replication checkpoint. In contrast, in non-cancer cells, a different protein, CK1?1, phosphorylates Claspin when DNA replication is blocked. The reason for this difference is because cancer cells have high amounts of Cdc7, while non-cancerous cells have low amounts of Cdc7 and relatively high amounts of CK1?1. The results show an example of differential cellular strategies to deal with crisis between cancer and non-cancer cells.

Cancer cells are generally more sensitive to replication block than non-cancer cells, since cellular protection mechanisms are often compromised in cancers. Understanding how cells respond to cellular crises such as DNA replication block is crucial to developing new strategies for cancer treatments. Hisao Masai, Ph.D., the senior author of the E-life article, says, "We can take advantage of the different mechanisms utilized by cancer and non-cancer cells to devise a way to specifically target cancer cells. Our findings suggest that inhibiting Cdc7 will efficiently inactivate the safe-guard system against replication block selectively in cancer cells, leading to their clearance by cell death. Indeed, we and others have developed low molecular-weight compounds that specifically inhibit Cdc7 as candidate anti-cancer agents."
-end-
Yang CC, Kato H, Shinde M, Masai H. Cdc7 activates replication checkpoint by phosphorylating the Chk1-binding domain of Claspin in human cells. Elife. 2019 Dec 31;8. pii: e50796. doi: 10.7554/eLife.50796. PubMed PMID: 31889509; PubMed Central PMCID: PMC6996922.

About the Tokyo Metropolitan Institute of Medical Science

The Tokyo Metropolitan Institute of Medical Science is a public interest foundation funded by the Tokyo metropolitan government. Its goal is to pursue basic and medical research to improve the health and well-being of the people of Tokyo and worldwide. The Institute contains 35 research laboratories, and was ranked as the top research institute in life sciences in Japan by Nature Index 2018 Japan.

Tokyo Metropolitan Institute of Medical Science

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.